Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Posttranslational modification of proteins by the addition of the small protein SUMO (see SUMO1\; MIM 601912), or sumoylation, regulates protein structure and intracellular localization. Additionally we are shipping SAE1 Proteins (20) and SAE1 Kits (9) and many more products for this protein.
Showing 10 out of 134 products:
Human Monoclonal SAE1 Primary Antibody for IF, WB - ABIN395192
Ewing, Chu, Elisma, Li, Taylor, Climie, McBroom-Cerajewski, Robinson, OConnor, Li, Taylor, Dharsee, Ho, Heilbut, Moore, Zhang, Ornatsky, Bukhman, Ethier, Sheng, Vasilescu, Abu-Farha, Lambert, Duewel et al.: Large-scale mapping of human protein-protein interactions by mass spectrometry. ... in Molecular systems biology 2007
Show all 5 references for ABIN395192
Chimpanzee Polyclonal SAE1 Primary Antibody for EIA, IF - ABIN401032
Lois, Lima: Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1. in The EMBO journal 2005
Show all 4 references for ABIN401032
Human Polyclonal SAE1 Primary Antibody for IHC (p), WB - ABIN389081
Desterro, Rodriguez, Kemp, Hay: Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1. in The Journal of biological chemistry 1999
Show all 3 references for ABIN389081
Cow (Bovine) Polyclonal SAE1 Primary Antibody for EIA, WB - ABIN401467
Gong, Li, Millas, Yeh: Molecular cloning and characterization of human AOS1 and UBA2, components of the sentrin-activating enzyme complex. in FEBS letters 1999
Show all 3 references for ABIN401467
Human Polyclonal SAE1 Primary Antibody for EIA, IHC (p) - ABIN4620441
Okuma, Honda, Ichikawa, Tsumagari, Yasuda: In vitro SUMO-1 modification requires two enzymatic steps, E1 and E2. in Biochemical and biophysical research communications 1999
Show all 3 references for ABIN4620441
the expression of SENP8 (show SENP8 Antibodies), SAE1, PIAS1 (show PIAS1 Antibodies), PIAS2 (show PIAS2 Antibodies) and ZMIZ1 (show ZMIZ1 Antibodies) is deregulated in the majority of PTC (show F9 Antibodies) tissues, likely contributing to the PTC (show F9 Antibodies) phenotype.
as it has been shown by flow cytometry analysis, specific knockdown of SAE1 slowed down the cell population at G0/G1 phase and induced apoptosis of RKO cells.
a four-generation pedigree with isolated terminal limb defects and a truncating mutation in ARHGAP31 (show ARHGAP31 Antibodies) underscores the relevance of sequencing ARHGAP31 (show ARHGAP31 Antibodies) in cases of isolated limb defects, irrespective of presence of a complete Adams-Oliver syndrome phenotype
The focal adhesion-localized CdGAP (show ARHGAP31 Antibodies) regulates matrix rigidity sensing and durotaxis.
Data demonstrate that cdGAP (show ARHGAP31 Antibodies) negatively regulates directed and random migration by controlling adhesion maturation and dynamics through the regulation of both adhesion assembly and disassembly.
Data indicate the role of anti-SUMO activating enzyme SAE1 and SAE2 (show RBBP8 Antibodies) antibody as marker of dermatomyositis.
specific interaction between negatively charged phospholipid PI(3,4,5)P3 and the stretch of polybasic residues preceding the RhoGAP (show ARHGAP1 Antibodies) domain regulates CdGAP (show ARHGAP31 Antibodies) activity in vivo and is required for its cellular functions.
Data show that the SAE2 (show RBBP8 Antibodies) subunit of the small ubiquitin-like modifier (SUMO (show SUMO1 Antibodies)) E1 is autoSUMOylated at residue Lys (show LYZ Antibodies)-236, and SUMOylation was catalyzed by Ubc9 (show UBE2I Antibodies) at several additional Lys (show LYZ Antibodies) residues surrounding the catalytic Cys (show DNAJC5 Antibodies)-173 of SAE2 (show RBBP8 Antibodies).
loss of SAE1/2 activity drives synthetic lethality with Myc (show MYC Antibodies); inactivation of SAE2 (show RBBP8 Antibodies) leads to mitotic catastrophe and cell death upon Myc (show MYC Antibodies) hyperactivation; findings in Myc (show MYC Antibodies)-high breast cancers suggest low tumor SAE1 and SAE2 (show RBBP8 Antibodies) correlates metastasis-free survival
Rho GTPase activating protein 31 (show ARHGAP31 Antibodies)
Posttranslational modification of proteins by the addition of the small protein SUMO (see SUMO1\; MIM 601912), or sumoylation, regulates protein structure and intracellular localization. SAE1 and UBA2 (MIM 613295) form a heterodimer that functions as a SUMO-activating enzyme for the sumoylation of proteins (Okuma et al., 1999
Cdc42 GTPase-activating protein
, rho GTPase-activating protein 31
, SUMO-1 activating enzyme E1 N subunit
, SUMO-1 activating enzyme subunit 1
, SUMO-activating enzyme subunit 1
, activator of SUMO1
, sentrin/SUMO-activating protein AOS1
, ubiquitin-like 1-activating enzyme E1A
, ubiquitin-like protein SUMO-1 activating enzyme
, ubiquitin-like (sentrin) activating enzyme E1A
, ubiquitin-like 1 (sentrin) activating enzyme E1A
, ubiquitin-like 1 (sentrin) activating enzyme subunit 1
, SUMO-activating enzyme E1 N subunit